Logo image of ROIV

ROIVANT SCIENCES LTD (ROIV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ROIV - BMG762791017 - Common Stock

22.45 USD
-0.23 (-1.01%)
Last: 12/23/2025, 8:00:01 PM
22.45 USD
0 (0%)
After Hours: 12/23/2025, 8:00:01 PM
Fundamental Rating

4

Taking everything into account, ROIV scores 4 out of 10 in our fundamental rating. ROIV was compared to 530 industry peers in the Biotechnology industry. While ROIV has a great health rating, there are worries on its profitability. ROIV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ROIV had negative earnings in the past year.
In the past year ROIV has reported a negative cash flow from operations.
In the past 5 years ROIV reported 4 times negative net income.
In the past 5 years ROIV always reported negative operating cash flow.
ROIV Yearly Net Income VS EBIT VS OCF VS FCFROIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B 3B 4B

1.2 Ratios

With an excellent Return On Assets value of -7.39%, ROIV belongs to the best of the industry, outperforming 85.09% of the companies in the same industry.
With an excellent Return On Equity value of -8.57%, ROIV belongs to the best of the industry, outperforming 88.11% of the companies in the same industry.
Industry RankSector Rank
ROA -7.39%
ROE -8.57%
ROIC N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROIV Yearly ROA, ROE, ROICROIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

Looking at the Gross Margin, with a value of 96.41%, ROIV belongs to the top of the industry, outperforming 96.42% of the companies in the same industry.
ROIV's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ROIV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
ROIV Yearly Profit, Operating, Gross MarginsROIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

More info and screens

9

2. Health

2.1 Basic Checks

ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ROIV has been reduced compared to 1 year ago.
The number of shares outstanding for ROIV has been increased compared to 5 years ago.
There is no outstanding debt for ROIV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ROIV Yearly Shares OutstandingROIV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
ROIV Yearly Total Debt VS Total AssetsROIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

ROIV has an Altman-Z score of 13.55. This indicates that ROIV is financially healthy and has little risk of bankruptcy at the moment.
ROIV's Altman-Z score of 13.55 is amongst the best of the industry. ROIV outperforms 85.09% of its industry peers.
ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.55
ROIC/WACCN/A
WACC9.23%
ROIV Yearly LT Debt VS Equity VS FCFROIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 2B 4B

2.3 Liquidity

ROIV has a Current Ratio of 33.70. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
ROIV's Current ratio of 33.70 is amongst the best of the industry. ROIV outperforms 98.49% of its industry peers.
A Quick Ratio of 33.70 indicates that ROIV has no problem at all paying its short term obligations.
The Quick ratio of ROIV (33.70) is better than 98.49% of its industry peers.
Industry RankSector Rank
Current Ratio 33.7
Quick Ratio 33.7
ROIV Yearly Current Assets VS Current LiabilitesROIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

4

3. Growth

3.1 Past

ROIV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.65%, which is quite good.
ROIV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -74.11%.
ROIV shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.56% yearly.
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
Revenue 1Y (TTM)-74.11%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-64.89%

3.2 Future

Based on estimates for the next years, ROIV will show a very strong growth in Earnings Per Share. The EPS will grow by 52.70% on average per year.
The Revenue is expected to grow by 108.81% on average over the next years. This is a very strong growth
EPS Next Y-407.96%
EPS Next 2Y-142.4%
EPS Next 3Y-59.74%
EPS Next 5Y52.71%
Revenue Next Year-78.75%
Revenue Next 2Y0.68%
Revenue Next 3Y104.33%
Revenue Next 5Y108.81%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ROIV Yearly Revenue VS EstimatesROIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
ROIV Yearly EPS VS EstimatesROIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ROIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ROIV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ROIV Price Earnings VS Forward Price EarningsROIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ROIV Per share dataROIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

ROIV's earnings are expected to decrease with -59.74% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-142.4%
EPS Next 3Y-59.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ROIV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ROIVANT SCIENCES LTD

NASDAQ:ROIV (12/23/2025, 8:00:01 PM)

After market: 22.45 0 (0%)

22.45

-0.23 (-1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)N/A N/A
Inst Owners64.96%
Inst Owner ChangeN/A
Ins Owners3.84%
Ins Owner Change5.08%
Market Cap15.61B
Revenue(TTM)20.33M
Net Income(TTM)-373.97M
Analysts85.56
Price Target24.76 (10.29%)
Short Float %4.59%
Short Ratio2.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)22.89%
Min EPS beat(2)-4.36%
Max EPS beat(2)50.15%
EPS beat(4)3
Avg EPS beat(4)58.4%
Min EPS beat(4)-4.36%
Max EPS beat(4)180.12%
EPS beat(8)6
Avg EPS beat(8)50.87%
EPS beat(12)7
Avg EPS beat(12)31.34%
EPS beat(16)9
Avg EPS beat(16)18.02%
Revenue beat(2)0
Avg Revenue beat(2)-74.21%
Min Revenue beat(2)-77.83%
Max Revenue beat(2)-70.59%
Revenue beat(4)0
Avg Revenue beat(4)-64.48%
Min Revenue beat(4)-86.28%
Max Revenue beat(4)-23.24%
Revenue beat(8)2
Avg Revenue beat(8)-34.24%
Revenue beat(12)5
Avg Revenue beat(12)-18.03%
Revenue beat(16)7
Avg Revenue beat(16)-4.01%
PT rev (1m)23.53%
PT rev (3m)27.01%
EPS NQ rev (1m)9.06%
EPS NQ rev (3m)6.01%
EPS NY rev (1m)12.68%
EPS NY rev (3m)10.32%
Revenue NQ rev (1m)2.2%
Revenue NQ rev (3m)-9.25%
Revenue NY rev (1m)-13.28%
Revenue NY rev (3m)-17.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 768.05
P/FCF N/A
P/OCF N/A
P/B 3.58
P/tB 3.58
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-1.47
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0.03
BVpS6.27
TBVpS6.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.39%
ROE -8.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.41%
FCFM N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 228.14%
Cap/Sales 71.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 33.7
Quick Ratio 33.7
Altman-Z 13.55
F-Score4
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)35.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.59%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
EPS Next Y-407.96%
EPS Next 2Y-142.4%
EPS Next 3Y-59.74%
EPS Next 5Y52.71%
Revenue 1Y (TTM)-74.11%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-64.89%
Revenue Next Year-78.75%
Revenue Next 2Y0.68%
Revenue Next 3Y104.33%
Revenue Next 5Y108.81%
EBIT growth 1Y-3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.43%
EBIT Next 3Y-1.08%
EBIT Next 5YN/A
FCF growth 1Y7.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.22%
OCF growth 3YN/A
OCF growth 5YN/A

ROIVANT SCIENCES LTD / ROIV FAQ

What is the ChartMill fundamental rating of ROIVANT SCIENCES LTD (ROIV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ROIV.


What is the valuation status of ROIVANT SCIENCES LTD (ROIV) stock?

ChartMill assigns a valuation rating of 0 / 10 to ROIVANT SCIENCES LTD (ROIV). This can be considered as Overvalued.


How profitable is ROIVANT SCIENCES LTD (ROIV) stock?

ROIVANT SCIENCES LTD (ROIV) has a profitability rating of 3 / 10.


What is the expected EPS growth for ROIVANT SCIENCES LTD (ROIV) stock?

The Earnings per Share (EPS) of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -407.96% in the next year.